July 2026 included several FDA drug and biologic approvals across a range of therapeutic areas. This timeline highlights the key alerts our publication covered throughout the month, giving readers a quick,...
The FDA approval provides physicians with a once-daily oral PCSK9 inhibitor option to reduce LDL-C in adults with high cholesterol, including those with heterozygous familial hypercholesterolemia.
In a post hoc analysis of the SURPASS-CVOT randomized clinical trial, researchers found that tirzepatide was associated with fewer cardiorenal events than dulaglutide in high-risk type 2 diabetes.
New guideline recommendations from the ACC/AHA and 9 partner organizations prioritize earlier treatment, refined atherosclerotic cardiovascular disease risk prediction, and broader use of lipid biomarkers...
A large observational cohort study published in Annals of Internal Medicine examined the effectiveness of statin therapy for primary prevention in adults with type 2 diabetes stratified by predicted 10-year...
In a long-term analysis of the ASPirin in Reducing Events in the Elderly trial cohort, investigators evaluated whether daily low-dose aspirin for primary prevention provides sustained cardiovascular benefit...
A large systematic review and meta-analysis published in the Journal of the American Heart Association evaluated evidence from 155 studies worldwide, identifying strong associations between several viral...
In a nationally representative cohort, adolescents and young adults with optimal cardiovascular health later had lower risks of gestational diabetes and hypertensive disorders of pregnancy than peers with...
